Ianalumab vs placebo in adults with Sjögren's disease and high symptom burden

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, double-blind, randomized, placebo-controlled Phase III trial. Participants with Sjögren's disease and high symptom burden are assigned to receive either ianalumab 300 mg subcutaneously or placebo every month for 52 weeks. The study uses strict eligibility criteria including seropositivity for anti-Ro/SSA and objective measures of gland function and dryness. The primary goal is to determine the efficacy and safety of ianalumab in reducing disease activity and symptoms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female participants ≥ 18 years of age or as per country-specific legal adult age, whichever is higher
* Classification of Sjögren's disease according to ACR/EULAR 2016 criteria.
* Seropositive for anti-Ro/SSA antibodies at screening
* SSSD oral dryness score ≥ 5 and overall SSSD summary score ≥5 collected over 14 consecutive days during the Screening 2 period
* Screening ESSDAI biologic and/or hematologic domain \> 0 Note: laboratory abnormalities for scoring must be confirmed as associated with Sjögren's disease and not be due to other underlying conditions.
* Stimulated whole salivary flow (sSF) rate \> 0.3 mL/min at screening
* Participants taking hydroxychloroquine (≤ 400 mg/day) are allowed to continue their medication, and must have been on a stable dose for at least 4 weeks prior to screening, which should be maintained throughout the 52 weeks of the blinded treatment period.
* Predniso(lo)ne ≤ 5 mg/day or equivalent are allowed for up to 16 weeks post-randomization.

Exclusion Criteria:

* Presence of another autoimmune rheumatic disease that is active and constitutes the principal illness, specifically:
* Systemic sclerosis (SSc)
* Any other associated connective tissue disease (e.g., lupus nephritis (LN), large vessel vasculitis (LVV), Sharp syndrome (mixed connective tissue disease)) that is active and requires immunosuppressive treatment outside the scope of this trial and would impede on Sjögren's disease organ domain assessments.
* Concurrent diagnosis or history of fibromyalgia or overlapping inflammatory diseases
* Prior treatment with B-cell-depleting therapy (e.g., rituximab, other anti-CD20 mAb, anti-CD22 mAb, or anti-CD52 mAb) within:
* 36 weeks prior to randomization, or
* As long as B-cell count is less than the lower limit of normal (LLN) or baseline value prior to receipt of previous B-cell-depleting therapy (whichever is lower) at Screening.
* Prior treatment with ianalumab
* Prior treatment with any of the following within the given period prior to Screening:
* Within 5 half-lives prior to Screening: iscalimab (anti-CD 40 mAb), belimumab (anti-BAFF mAb), abatacept (CTLA4-Fc Ig), anti-tumor necrosis factor alpha (TNFα) biologic agents, immunoglobulins (i.v./s.c.), plasmapheresis, any other investigational biologic medicines under investigation for Sjögren's disease
* Within 4 weeks OR drug-specific 5 half-lives elimination period (if longer than 4 weeks) prior to screening: i.v. or oral cyclophosphamide, mycophenolate mofetil (MMF), methotrexate, azathioprine, i.v. or oral cyclosporine A or any other immunosuppressants (e.g., JAK inhibitors or other kinase inhibitors).
* History of hypersensitivity to any of the study drugs or their excipients, or to drugs of similar chemical classes (e.g., mAb of IgG1 class) or to any of the constituents of the study drug formulation (sucrose, L-histidine hydrochloride/L-histidine, polysorbate 20).

Where it's running

• Sun Valley Arthritis Center Ltd
  Peoria, Arizona, United States Recruiting
• Unity Health Rheumatology
  Searcy, Arkansas, United States Recruiting
• Medvin Clinical Research
  Van Nuys, California, United States Recruiting
• Clinical Res Of W Florida
  Clearwater, Florida, United States Recruiting
• GNP Research
  Cooper City, Florida, United States Recruiting
• Clinical Research of West Florida Inc
  Tampa, Florida, United States Recruiting

+22 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: 1-888-669-6682

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Telitacicept for primary Sjögren’s with interstitial lung disease

  This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.

  Recruiting Peking University People's Hospital · Beijing · NCT07843381

• DDY391 in Sjögren's disease: see if it works and is safe

  This study tests whether DDY391 is effective and safe for people with Sjögren's disease over up to 52 weeks.

  Recruiting at 31 sites Phase 2 Novartis · Avondale, Arizona and 30 other locations · NCT07737743

• Test of HBM7020 in healthy adults and adults with autoimmune diseases

  This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Brisbane, Queensland · NCT07649265

• Ianalumab plus a thrombopoietin receptor agonist for adults with ITP or Evans syndrome

  This study will test whether adding ianalumab to a doctor's chosen TPO-RA is tolerable for adults with immune thrombocytopenia (and an exploratory group with Evans syndrome) who have had prior treatments and are on a stable TPO-RA dose.

  Recruiting at 23 sites Phase 2 Novartis · Chandler, Arizona and 22 other locations · NCT07421167

• Phase 1 safety test of XmAb657 in healthy adults and people with myositis, scleroderma, or Sjögren's

  This study will test whether subcutaneous injections of XmAb657 are safe and well tolerated in healthy adults and people with autoimmune diseases such as idiopathic inflammatory myopathies, systemic sclerosis, or primary Sjögren's syndrome.

  Recruiting Phase 1 Xencor, Inc. · Melbourne · NCT07284797

• Long-term follow-up of ianalumab with or without stopping treatment for people with lupus nephritis

  This 2-year extension will test whether continuing or stopping ianalumab keeps kidney disease under control and is safe for people with lupus nephritis who completed the core study.

  Recruiting at 50 sites Phase 3 Novartis · Orchard Park, New York and 52 other locations · NCT06711887

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.